Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Feb 11;38(23):4590–4604. doi: 10.1038/s41388-019-0743-4

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2019

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 6 — IGFBP5 is a transcriptional target of PKNOX2 in GC. a PKNOX2 regulated genes were identified by Human Cancer PathwayFinder PCR Array. Genes with <0.5-fold or >2-fold change in AGS overexpressing PKNOX2 as compared with control AGS cells. b PCR validation of differentially expressed genes by real-time PCR and RT-PCR, respectively. c PKNOX2 positively regulated IGFBP5 protein expression. d PKNOX2 directly binds to IGFBP5 promoter. Binding motif for PKNOX2 was predicted by JASPAR database (red squares). ChIP-PCR using anti-Myc-tag or anti-PKNOX2 revealed direct binding of PKNOX2 to the promoter region of IGFBP5. e Correlation between the expression of PKNOX2 and IGFBP5 in GC patients from the TCGA cohort (P < 0.001, R = 0.6383). f IGFBP5 knockdown in AGS cells overexpressing PKNOX2 was validated by RT-PCR and Western blot. g The tumor suppressive effect of PKNOX2 was partly dependent on IGFBP5. IGFBP5 knockdown partly abolished the growth inhibitory effect of PKNOX2 on cell viability and colony formation in AGS cells (both P < 0.0001). h Knockdown of IGFBP5 in GES1 cells. i IGFBP5 silencing in GES1 cells promoted cell viability (P < 0.01) and colony formation in GES1 cells(siIGFBP5-1, P < 0.0001;siIGFBP5-2, P < 0.01). (**P < 0.01; ***P < 0.0001)